Axcelis Technologies, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. The filing also reports unaudited fourth-quarter results. Axcelis designs, manufactures and services semiconductor ion-implantation equipment; ion implantation represented 95.1% of FY2019 revenue. The company cited weak industry conditions, particularly lower memory-sector spending.
Financial results and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | $343.0 million | $442.6 million |
| Systems revenue | $202.6 million | $280.4 million |
| Aftermarket revenue | $140.4 million | $162.2 million |
| Gross profit / margin | $144.2 million / 42.0% | $179.6 million / 40.6% |
| Operating income / margin | $24.2 million / 7.1% | $60.0 million / 13.6% |
| Net income | $17.0 million | $45.9 million |
| Diluted EPS | $0.50 | $1.35 |
| Cash from operating activities | $(13.6) million | $47.0 million |
Fourth-quarter revenue was $107.7 million, versus $105.7 million in Q4 2018; net income was $9.7 million versus $8.5 million, and diluted EPS was $0.29 versus $0.25.
At year-end, cash and cash equivalents were $139.9 million, working capital was $307.0 million, total assets were $548.1 million, and stockholders’ equity was $419.4 million. Axcelis reported no bank debt, but had a $48.5 million sale-leaseback finance obligation and $5.7 million of operating lease liabilities. FY2019 capital expenditures were $12.0 million; management projected approximately $7.5 million for 2020. The company used $17.7 million for share repurchases and had $32.3 million remaining under its authorization at year-end.
Changes and operating developments
- Revenue declined 22.5% year over year, primarily due to fewer Purion systems sold; systems revenue fell 27.8%. Operating income declined 59.6% and net income declined 62.9%.
- Despite lower sales, gross margin improved to 42.0% from 40.6%, reflecting improved Purion system margins and cost-reduction efforts. R&D expense rose to $53.9 million, or 15.7% of revenue, from $51.9 million, as the company continued product development.
- Aftermarket revenue decreased to $140.4 million from $162.2 million. Customer Support and Innovation revenue represented 40.9% of total revenue, compared with 36.6% in 2018.
- Year-end systems backlog, including deferred systems revenue, increased to $99.3 million from $65.1 million. Q4 bookings were $77.2 million versus $42.1 million in Q4 2018. Orders may be canceled or rescheduled, and management cautions that backlog is not a reliable indicator of future sales.
- Axcelis launched four Purion implanter extensions targeting mature-process applications including image sensors and power devices. Management said 2019 was the first full industry cycle through which the company remained profitable.
Outlook, risks and other matters
Management said it expected to continue delivering consistent, profitable financial performance in 2020 and identified revenue growth, year-over-year gross-margin improvement, Purion expansion, customer support growth and shareholder returns as strategic priorities. The filing provides no quantified revenue or earnings guidance. It projected approximately $7.5 million in 2020 capital expenditures.
- Risks include semiconductor capital-spending cyclicality, customer concentration, competition, product-development and acceptance risks, and reliance on suppliers and aftermarket demand. The top ten customers represented 74.1% of FY2019 sales; three customers individually accounted for 18.2%, 14.2% and 12.0%.
- International sales were 89.4% of revenue, with substantial Asia exposure. The filing identified trade tensions and, as of early 2020, the uncertain potential effects of COVID-19 on customers, suppliers and operations.
- Operating cash flow turned negative, largely amid working-capital movements, including inventory and accounts payable/current liabilities. Management nevertheless believed available cash and borrowing capacity would meet anticipated short- and long-term needs; the company had no credit facility.
- The $109.6 million of scheduled sale-leaseback payments includes $61.0 million of interest; the recorded obligation was $48.5 million. Purchase-order commitments were $62.4 million. Outstanding letters of credit and surety bonds totaled $10.6 million.
- FY2019 tax expense was $3.9 million, with an 18.6% effective rate. Deferred tax assets were $68.1 million, including an $8.3 million valuation allowance; realization depends partly on future taxable income. No litigation was identified as likely to have a material adverse effect.
- Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. The company reported effective disclosure controls and financial-reporting controls.
Important facts for investors to verify
- Whether systems bookings and backlog convert into shipments, customer acceptance and recognized revenue, given cancellation and deferral risks.
- Whether gross-margin gains persist as revenue recovers or weakens, and whether ongoing R&D spending supports commercial adoption of new Purion products.
- How the negative operating cash flow, inventory growth and working-capital movements develop in subsequent periods.
- Exposure to major customers, Asia, trade restrictions, COVID-19-related disruptions and constrained component suppliers.
- The scale and cash demands of the sale-leaseback obligation, repurchases, capital spending and other commitments, alongside the company’s stated 2020 outlook.